Opaleye Management Inc. Trevi Therapeutics, Inc. Transaction History
Opaleye Management Inc.
- $364 Million
- Q1 2025
A detailed history of Opaleye Management Inc. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 795,000 shares of TRVI stock, worth $4.84 Million. This represents 1.38% of its overall portfolio holdings.
Number of Shares
795,000
Previous 2,317,500
65.7%
Holding current value
$4.84 Million
Previous $9.87 Million
49.35%
% of portfolio
1.38%
Previous 1.94%
Shares
9 transactions
Others Institutions Holding TRVI
# of Institutions
142Shares Held
85.3MCall Options Held
1.5MPut Options Held
304K-
Nea Management Company, LLC Timonium, MD11.4MShares$69.2 Million6.78% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$62.5 Million4.06% of portfolio
-
Rubric Capital Management LP New York, NY4.54MShares$27.6 Million0.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.84MShares$23.4 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.49MShares$21.2 Million5.95% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $355M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...